UK markets open in 2 hours 24 minutes
NIKKEI 225
37,945.64 +317.16 (+0.84%) HANG SENG
17,626.75 +342.21 (+1.98%) CRUDE OIL
83.88 +0.31 (+0.37%) GOLD FUTURES
2,347.90 +5.40 (+0.23%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,405.28 -19.89 (-0.04%)
Daiichi Sankyo Co Ltd (D4S.DU)
Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
At close: 07:31PM CEST
| Previous close | 27.93 |
| Open | 28.08 |
| Bid | 28.02 x 0 |
| Ask | 28.73 x 0 |
| Day's range | 27.96 - 28.38 |
| 52-week range | 22.41 - 33.90 |
| Volume | |
| Avg. volume | 5 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Yahoo FinanceAstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
ZacksAtossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
ZacksMerck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
© 2024 Yahoo. All rights reserved.